Clinical TrialAug 12, 2026, 04:07 PM
Aligos Initiates Phase 1 Study for ALG-170675 in Chronic HBV
AI Summary
Aligos Therapeutics announced the initiation of a Phase 1 study for ALG-170675, an investigational next-generation antisense oligonucleotide (ASO) for chronic hepatitis B virus (HBV) infection. The study, conducted in China by partner Xiamen Amoytop Biotech, will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALG-170675 in healthy participants, with a chronic HBV patient cohort expected in Q4 2026. ALG-170675 is optimized for HBsAg RNA inhibition and immuno-activation, aiming to enhance functional cure rates.
Key Highlights
- Aligos initiated Phase 1 study for ALG-170675 in chronic HBV.
- Study conducted in China by partner Xiamen Amoytop Biotech.
- ALG-170675 is a next-generation antisense oligonucleotide (ASO).
- Designed for functional cure in chronic hepatitis B virus (HBV).
- Single (SAD) and multiple (MAD) ascending doses planned for healthy participants.
- Chronic HBV patient cohort expected to start in Q4 2026.
- ALG-170675 optimized for HBsAg RNA inhibition and immuno-activation.
Price Impact
More from ALGS